Raloxifene Hydrochloride Patent Expiration
Raloxifene Hydrochloride is Used for preventing and treating osteoporosis in postmenopausal women and inhibiting bone resorption, as well as for preventing breast cancer. It was first introduced by Eli Lilly And Co
Raloxifene Hydrochloride Patents
Given below is the list of patents protecting Raloxifene Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Evista | US6458811 | Benzothiophenes formulations containing same and methods |
Mar 10, 2017
(Expired) | Lilly |
| Evista | US6797719 | Benzothiophenes, formulations containing same, and methods |
Mar 10, 2017
(Expired) | Lilly |
| Evista | US6894064 | Benzothiophenes, formulations containing same, and methods |
Mar 10, 2017
(Expired) | Lilly |
| Evista | US8030330 | Benzothiophenes, formulations containing same, and methods |
Mar 10, 2017
(Expired) | Lilly |
| Evista | US5478847 | Methods of use for inhibiting bone loss and lowering serum cholesterol |
Mar 02, 2014
(Expired) | Lilly |
| Evista | US5811120 | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
Mar 02, 2014
(Expired) | Lilly |
| Evista | US5972383 | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
Mar 02, 2014
(Expired) | Lilly |
| Evista | USRE39050 | Methods of use for inhibiting bone loss and lowering serum cholesterol |
Mar 02, 2014
(Expired) | Lilly |
| Evista | US5393763 | Methods for inhibiting bone loss |
Jul 28, 2012
(Expired) | Lilly |
| Evista | US5457117 | Method for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[B][2-(piperidin-1-yl)ethoxyphenylimethanone hydrochloride |
Jul 28, 2012
(Expired) | Lilly |
| Evista | US6906086 | Methods for inhibiting bone loss |
Jul 28, 2012
(Expired) | Lilly |
| Evista | USRE38968 | Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride |
Jul 28, 2012
(Expired) | Lilly |
| Evista | USRE39049 | Methods for inhibiting bone loss |
Jul 28, 2012
(Expired) | Lilly |
Raloxifene Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Raloxifene Hydrochloride Generic API Manufacturers
Several generic applications have been filed for Raloxifene Hydrochloride. The first generic version for Raloxifene Hydrochloride was by Teva Pharmaceuticals Usa and was approved on Mar 4, 2014. And the latest generic version is by Cadila Pharmaceuticals Ltd and was approved on Aug 18, 2020.
Given below is the list of companies who have filed for Raloxifene Hydrochloride generic, along with the locations of their manufacturing plants worldwide.
1. AMNEAL PHARMS
Amneal Pharmaceuticals has filed for 1 generic for Raloxifene Hydrochloride. Given below are the details of the strengths of this generic introduced by Amneal Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG | tablet | Prescription | ORAL | AB | Apr 8, 2016 |
2. AUROBINDO PHARMA
Aurobindo Pharma Ltd has filed for 1 generic for Raloxifene Hydrochloride. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG | tablet | Prescription | ORAL | AB | Aug 28, 2015 |
Manufacturing Plant Locations New
Aurobindo Pharma's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||
| United States |
| |||||||||
3. CADILA PHARMS LTD
Cadila Pharmaceuticals Ltd has filed for 1 generic for Raloxifene Hydrochloride. Given below are the details of the strengths of this generic introduced by Cadila Pharms Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG | tablet | Prescription | ORAL | AB | Aug 18, 2020 |
4. GLENMARK PHARMS LTD
Glenmark Pharmaceuticals Ltd has filed for 1 generic for Raloxifene Hydrochloride. Given below are the details of the strengths of this generic introduced by Glenmark Pharms Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG | tablet | Prescription | ORAL | AB | Mar 22, 2016 |
5. INVAGEN PHARMS
Invagen Pharmaceuticals Inc has filed for 1 generic for Raloxifene Hydrochloride. Given below are the details of the strengths of this generic introduced by Invagen Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG | tablet | Prescription | ORAL | AB | Sep 24, 2014 |
6. SCIEGEN PHARMS INC
Sciegen Pharmaceuticals Inc has filed for 1 generic for Raloxifene Hydrochloride. Given below are the details of the strengths of this generic introduced by Sciegen Pharms Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG | tablet | Prescription | ORAL | AB | Oct 12, 2016 |
7. TEVA PHARMS USA
Teva Pharmaceuticals Usa has filed for 1 generic for Raloxifene Hydrochloride. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG | tablet | Prescription | ORAL | AB | Mar 4, 2014 |
8. WATSON LABS INC
Watson Laboratories Inc has filed for 1 generic for Raloxifene Hydrochloride. Given below are the details of the strengths of this generic introduced by Watson Labs Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG | tablet | Prescription | ORAL | AB | Jan 21, 2015 |